FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease - FDA Press Releases

FDA approves Koselugo (selumetinib) for the treatment of pediatric patients, 2 years and older, with neurofibromatosis type 1 (NF1), a genetic disorder of the nervous system causing tumors to grow on nerves.

from FDA Press Releases RSS Feed https://ift.tt/2Xra0YD
via IFTTT